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Abstract 
Background: Severe symptoms of COVID-19 could be actually life-threatening and fatal. No effective treatment 
has been proposed yet. Plasma from COVID19 recovered patients may be effective according to past similar 
studies of some other viral infections. 
Materials and Methods: This study was conducted at the infectious disease ward of Shahid Labbafi Nejad 
Hospital (Tehran, Iran) from 3rd of April 2020 up until 3rd of May 2020. Clinical information for the 12 patients, 
before and after receiving convalescent plasma transfusion was obtained from a review of the hospital computer 
medical system retrospectively and analyzed. 
Results: Out of 12 patients with Covid-19 who received convalescent plasma, 7 patients were male (58.3%) 
and 5 were female (41.7%). The mean age of the patients was 52 years. Among them, 50% (n=6), improved 
and discharged and the rest of them died. Mean O2 saturation of patients with final outcome of death and 
discharged before plasma therapy were 67 (33%) and 77 (83%), respectively, an improvement, defining partial 
resolution of lesions of chest CT scan or stop in progression of infiltrations was detected in all of 6 discharged 
patients. 
Conclusion: Convalescent plasma may have effective role in improving O2 saturation, lymphopenia and CT scan 
lesions and also decreasing inflammatory factors of cases with severe manifestations but could not change 
prognosis for critically ill patients. Therefore, an early administration of convalescent plasma may be helpful. 
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Introduction 
Treatment of COVID-19 patients with severe and 
critical symptoms has become a serious global 
challenge. Presently, no particular treatment has been 
effective for critically ill patients. Oxygenation, 
combination of antivirals and some drugs such as 
remdesivir, were somewhat hopeful for severe and 
critical patients. Current data are not sufficient and 
adequate, yet1. Plasma from COVID-19 recovered 
patients has antibodies to the virus and it may be used 
as an effective treatment2.  
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About 15 years ago plasma or immunoglobulins of 
patients recovered from severe acute respiratory 
syndrome (SARS) was used as a salvage therapy for 
patients with critically ill presentations. This study 
together with several other studies has shown decrease 
in mortality and hospital stay of SARS patients after 
using convalescent plasma3-5. Moreover, using plasma 
of improved patients has been reported in the outbreak 
of other infections, such as H1N1 influenza, Ebola, 
and MERS (Middle East respiratory syndrome)2, 6. 
Theoretically prescribing convalescent plasma can be 
effective for treatment of COVID-19 patients4. 
Recently, the US Food and Drug Administration has 
approved the use of convalescent plasma for treatment 
of people who are critically ill with COVD-192. 
However, the potential clinical advantages and 
disadvantages of convalescent plasma in COVID-19 
remain unclear; accordingly, we evaluated response to 
therapy and outcome of 12 severe and critical COVD-
19 patients who received convalescent plasma, as part 
of the treatment of their diseases. 
Methods 
This study was conducted at the infectious disease 
ward of Shahid Labbafi Nejad Hospital (Tehran, Iran), 
one of the educational hospitals of Shahid Beheshti 
University of Medical Sciences, during a period 
starting from 3rd of April 2020 up until 3rd of May 
2020, when the follow up ended. 
Clinical information for the 12 patients, before and 
after receiving 1 dose (650cc) convalescent plasma 
transfusion was obtained from a review of the hospital 
computer medical system retrospectively and they 
included the following: demographic data, days of 
admission from symptom onset, presenting 
symptoms, data about different treatments; including 
mechanical ventilation, antiviral therapies, laboratory 
data (White blood cell count, lymphocyte count, 
inflammatory factors C-reactive protein (CRP), 
Lactate Dehydrogenate (LDH), Blood type, 
medication administration, O2 saturation rate and 
ventilator use data. The medical history of the patients 
was reviewed for any underlined diseases, as well.  
All patients met such inclusion criterion as: (1) 
symptoms suggestive of COVID-19 pneumonia 
(fever, cough, dyspnea, myalgia); (2) chest computed 
tomography (CT) scan suggestive of COVID-19  
Patients who were classified as critical or severe cases 
received plasma. Critical patient was defined as a 
patient with respiratory failure, shock or multiple organ 
dysfunction or failure and cases with dyspnea, 
respiratory rate ≥30 breaths per min, oxygen 
saturation≤ 93% with increase in lung infiltrate >50% 
in 24-48h were described as severe cases7. A total of 12 
donors of convalescent plasma were between the ages 
of 35 to54years. The donors had been well for at least 
10 days, with an average of anti-COVID 19 IgG 1161.5 
mg/dl. 
Results 
Out of 12 patients with Covid-19 who received 
convalescent plasma between April 3rd and May 3rd, 
2020, 7 patients were male (58.3%) and 5 were female 
(41.7%). The mean age of the patients was 52 years. 
The most common symptoms were dyspnea, myalgia 
and fatigue; noted amongst 91.7% (11/12), 75% (9/12) 
and 75% (9/12) (Table1); respectively. The mean 
length of hospital stay was 23.66 days for all 12 
patients.  
“A” group blood type had the highest percentage of 
blood types in patients. The most common underlined 
disease was diabetes (5/7) 41.7%. 
The mean O2 saturation of all 12 cases without O2 
supplement therapy was 84% at the admission and 
72.5% just before transfusion of plasma. Only one of 
these patients was receiving mechanical ventilation at 
the time of transfusion. Although. intubation was 
occurred in average 8.57 days after admission for 7 of 
our study cases.  
Table 2 shows details of laboratory results at admission 
time, before and after convalescent plasma transfusion.  
All of 12 patients had bilateral grand glass opacities in 
chest CT scan imaging before plasma transfusion and 2 
patients had also consolidation. Moreover, 5 patients 
showed some degree of crazy paving pattern. An 
improvement, defining partial resolution of lesions of 
chest CT scan or stop in progression of infiltrations was 
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detected in all of 6 discharged patients (Fig. 2).  
Among our patients, 50% (6), improved and 
discharged after receiving plasma and the rest of them 
died. The cause of death of 5 of 6 patients were 
classified as ARDS and 1 patient (number 5) died of 
septic shock and Klebsiella pneumonia was detected 
in two blood cultures, just before death. 
In addition to hydroxychloroquine, which was 
prescribed to all of the study patients, half of the 
patients received Kaletra (Lopinavir- Ritonavir) 
400/100 mg twice a day, and the other half received 
Favipiravir, 1200mg for loading 600mg every 8 hours 
(Table 3). 
In the context of a research project, Interferon β1-a 12 
 
Figure 1. Changes of mean CRP level, mean Lymphocyte count and mean LDH level of Patients Receiving Convalescent Plasma 




Figure 2. A 19 years old woman a known case of multiple sclerosis (case number 1), presented with fever, fatigue and myalgia. The first 
Chest CT scan showed bilateral grand glass opacities (GGO) and consolidation (A, B), she received hydoxychloroquine and Kaletra but 
fever was continued and O2 saturation was decreased, then interferon beta1-a was added but the general appearance of the patient became 
worse with the addition of shortness of breath and decreasing o2 saturation. Convalescent plasma was administrated 25 days after 
admission and after 7 days clinical and radiological manifestation were improved (C, D). 
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million unit in 3 subcutaneous doses were 
administrated for 6 patients, in addition to other 
regimens. 
Discussion 
In this study, 12 patients who were severely or 
critically ill with COVID-19 were treated with 
convalescent plasma. Previous studies have reported 
the use of convalescent plasma transfusion in the 
treatment of various infections. In addition to antiviral 
treatment, virus specific neutralizing antibody, may 
improve viral clearance and interfere the entrance of 
virus into target cells, remain the main mechanism for 
the combating the diseases by the host8. 
Among 12 patients in the study, 6 patients showed 
improved clinical manifestations, so they were 
discharged with good general condition. The mean O2 
saturation of the discharged patients was about 10% 
higher than the dead group (77.83% vs.67.33%) at the 
admission time, Therefore, it raises the possibility that 
severe cases had better response to plasma therapy in 
comparison to the critical patients. 
Without considering the outcome, our results indicate 
that the average of CRP, as an inflammatory biomarker 
was decreased in Posttransfusion time compared to the 
admission time. It seems convalescent plasma has been 
Table 1: Clinical Characteristic of SARS-CoV-2-Infected Patients Who Received Convalescent Plasma. 
 1 2 3 4 5 6 7 8 9 10 11 12 
Gender  F M M F M M M F F M M F 
Age 19 56 52 71 38 41 26 83 81 45 58 54 
Blood Type B AB A A   B O A AB O O B A 
Fever  + - + - - - + - + + + + 
Cough - + - - + + + + + + + + 
Myalgia  + + + - - + + + + + - + 
Dyspnea - + + + + + - + + + + + 
Fatigue  + + + + + - + - + + - + 
Length of 
hospital stayed 












94 65 89 68 73 60 94 95 60 65 88 95 








25 16 7 6 8 5 8 16 20 3 21 7 
Past diagnosis   
Diabetes  - + - - - + - + + + - - 
Hypertension  - - - - - - - + - - - - 
Chronic kidney 
disease  
- - - - - + - + - - - - 
Wegner  - - - + - - - - - --  + 
Ischemic heart 
disease 
- - - - - - - - + - - - 
Multiple 
sclerosis 
+ - - - - - - - - - - - 
Psoriasis  - - + - - - - - - - - - 
Outcome   Disch
arged   
Dead Disch
arged   
Dead Dead Dead Discharged   Discharged   Dead Dead Discharged   Discharged   
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effective in reducing inflammatory factors. Study of 
Shen and colleagues showed similar results8. But the 
dead cases of our research had higher CRP level in 
comparison of discharged patients at both admission 
and post-transfusion time (Table 4 & Fig. 1). As it is 
mentioned in many articles, high level of CRP of 
COVID-19 patients may indicate severity of the 
disease 10,11. 
The number of leukocytes did not show any difference 
before and after the plasma transfusion. But 
lymphocyte count of all of 12 cases was increased 
after receiving plasma. The dead group had lower 
mean lymphocyte count at the admission time (Table 
4). It could be a predictor worse prognosis for them. 
The relation between lymphopenia and prognosis has 
been discussed in some articles11-13. There was an 
increase in the median of lymphocyte count and a 
decrease of LDH level for all patients after plasma 
transfusion which was consistent with the pervious and 
similar study8. LDH level could be an indicator of lung 
injury for critically ill COVID-19 patients11. In our 
study, the median level of LDH among dead patients 
which showed critical manifestations and lower O2 
saturation at the admission time was higher than 
patients with improved outcome (Table 4 and Fig. 1).  
The present study indicates that there is an association 
between diabetes and death of patients (Table 1) 
comorbidities and underlying diseases have been 
Table 2: Comparison of laboratory results at admission time, before and after convalescent plasma transfusion. 






41 36 20 160 50 150 22 41 28 87 40 77 62.66 
Just before 
transfusion 
69 42 32 160 77 60 25 38 49 41 45 60 58.16 
Posttransfusion 22 50 16 56 56 45 5 35 140 50 25 8 42.33 
WBC count 




3900 5900 9200 22100 8500 6800 7300 6600 3500 5700 7800 2300 7442 
Just before 
transfusion 
3500 7500 13100 16200 14500 5800 10000 7000 9100 6400 16800 4100 9500 
Posttransfusion 5200 4100 8200 8600 6800 8400 7000 7500 2100 5350 6800 19000 7420 
Lymphocyte 
\ml 
             
Admission to 
hospital 
390 1298 1380 105 1700 340 2409 1660 1400 855 780 437 1062.83 
Just before 
transfusion 
350 1875 1310 810 1450 1450 1400 1050 2275 640 2016 145 1110 






130 167 345 183 210 381 190 284 166 250 160 135 216 
Just before 
transfusion 
145 135 400 207 219 210 125 220 151 146 190 216 197 
Posttransfusion 168 124 225 90 85 184 165 280 100 90 155 195 155.08 
LDH    
Admission to 
hospital 
471 621 420 980 710 887 695 372 880 280 661 548  627.08 
Just before 
transfusion 
601 500 400 990 590 890 690 300 875 913 601 460 650.83 
Posttransfusion 224 480 320 685 520 760 420 250 435 895 442 250 473.41 
Albumin   
Admission to 
hospital 
2.2 2.8 2.9 2.5 2.4  3.5 3.8 3.4 3.5 3.4 2.9 3.9 3.1 
Just before 
transfusion 
2.1 2.6 2.2 2.4 2.3 3.4 2.9 3.0 3.2 4.2  2.6 3.5 2.86 
Posttransfusion 3.2 2.0 3.2 2.8 3.1 1.7 3.2 3.2 3.1 3.8 2.2 2.2 2.8 
 
 
Sali et al.                     Effects of Adding Convalescent Plasma Therapy for Treatment of COVID-19 Patients with Severe … 
NBM                                                                            44                                     Novelty in Biomedicine 2021, 2, 39-45 
suggested as predictors of poor prognosis in many 
articles14-16. Regardless the treatments achieved for 
patients, diabetes should be considered as an 
important risk factor for mortality, diseases 
progression and lung injury. So, diabetic Covid 19 
patients may need serious attention and care16, 17. 
In our study, convalescent plasma was used as a 
salvage therapy. Thus, before plasma therapy, patients 
received different types of treatment (Table 3). 6 
patients received Interferon β1-a in which 4 of them 
were among patients with discharged or improved 
outcome. Currently, some studies show encouraging 
findings with Interferon β1 therapy at the early stages 
of COVID-19 diseases18,19.  
In the present study, patients with better outcome and 
response to plasma had generally better condition in 
O2 saturation and laboratory tests at the admission 
time and before plasma transfusion (Table 4). 
The present study has some limitations; the number of 
study cases was small and limited and the control 
group was not defined for them. All patients received 
different types of antiviral agents before and 
concurrent with plasma therapy. Different time of 
transfusion of plasma from the admission time may 
affect different outcomes. Finally, we had limitation for 
measuring of viral load before and after plasma therapy. 
Correlation of viral loads with disease severity has been 
reported in some studies and neutralizing antibodies of 
plasma may improve viral clearance8. 
Conclusion 
Convalescent plasma may have effective role in 
improving O2 saturation, lymphopenia and CT scan 
lesions and also decreasing inflammatory factors of 
cases with severe manifestations but could not change 
prognosis for critically ill patients. So, an early 
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 Table 4: Changes of CRP level, Mean Lymphocyte count and LDH level of Patients Receiving Convalescent Plasma 
Transfusion at admission time, before and after transfusion, considering the outcomes. 
  CRP1 CRP2 CRP3 Lymph1 Lymph2 Lymph3 LDH1 LDH2 LDH3 
Discharged 40/16 44/83 18/5 1176 1045/16 2260 527/83 508/66 317/66 
Dead 85/16 71/5 66/16 949/66 1416/66 1455 726/33 793 629/16 
Total 62/66 58/165 42/33 1062/83 1230/91 1857/5 627/08 650/83 473/41 
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